Augmentin Brand Tablets and Suspensions XR and ES-600 U.S. Brand Verification

Augmentin: U.S. Brand Product Guide

Augmentin is a U.S. prescription antibiotic brand containing two active components: amoxicillin, a penicillin-class antibacterial, and clavulanate potassium, a beta-lactamase inhibitor. The combination is used for certain bacterial infections when the organisms involved are susceptible and the prescribing circumstances support its use. Although Augmentin is commonly associated with amoxicillin, it is not the same medicine as amoxicillin alone. The clavulanate component changes the product's antibacterial coverage and creates formulation-specific considerations that matter when interpreting a prescription or pharmacy listing.

The standard Augmentin brand encompasses immediate-release oral tablets, chewable tablets, and powders that are prepared as oral suspensions. Related branded formulations include Augmentin XR, an extended-release tablet, and Augmentin ES-600, a distinct oral suspension with a different amoxicillin-to-clavulanate proportion. These products share active ingredients but are not universally interchangeable. The FDA prescribing information distinguishes their strengths, administration characteristics, patient populations, and approved uses. Understanding these differences helps patients identify the actual product being prescribed without treating a familiar brand name as proof that every formulation serves the same purpose.

For U.S. patients comparing prescriptions, pharmacy listings, or product information, the practical questions are whether a product is labeled as Augmentin or a generic equivalent, which dosage form and strength the prescription specifies, and whether a licensed pharmacy can actually dispense the requested product. FDA approval and a historical brand listing do not establish current inventory at a particular pharmacy. This guide explains the standard Augmentin brand and its relationship to related formulations, while detailed generic-product information belongs in amoxicillin/clavulanate and separate cost comparisons belong in Augmentin price guide. Antibiotic treatment requires an appropriate clinical assessment and a valid prescription.

What Is Augmentin as a U.S. Prescription Brand?

Augmentin is the proprietary name associated with certain FDA-approved oral products containing amoxicillin and clavulanate potassium. Amoxicillin interferes with bacterial cell-wall synthesis, while clavulanate inhibits certain beta-lactamase enzymes that would otherwise inactivate susceptible penicillin-class antibiotics. The combination can therefore retain activity against some beta-lactamase-producing bacteria for which amoxicillin alone may be inadequate. Its usefulness still depends on the organism, resistance mechanisms, infection site, and clinical circumstances.

The brand name identifies a regulated drug-product family rather than a single universal tablet. FDA labeling includes multiple dosage forms with different amounts and proportions of the two active components. A prescription for an immediate-release tablet should not automatically be interpreted as a prescription for an extended-release tablet or a concentrated pediatric suspension. The exact formulation is part of the medication identity.

Augmentin is not an over-the-counter antibiotic in the United States. It is not an appropriate self-treatment for viral respiratory illnesses, and its broader activity relative to plain amoxicillin does not make it a universally preferable antibiotic. The FDA label emphasizes use for infections caused by susceptible bacteria, while unnecessary antibiotic exposure contributes to resistance and avoidable adverse effects. Readers comparing the two medicines can explore the distinctions in Augmentin vs amoxicillin, including their different ingredient compositions and prescribing considerations.

The distinction between a brand and its active ingredients also matters when reading pharmacy information. A product advertised or displayed using the name Augmentin may ultimately be dispensed as a generic amoxicillin/clavulanate product when legally permitted and appropriate for the prescription. The container label and pharmacy dispensing record, rather than the search-result headline, establish what was actually supplied.

Standard Augmentin Tablets, Chewables and Oral Suspensions

Standard Augmentin products are immediate-release formulations. The FDA's July 2026 prescribing information identifies conventional film-coated tablets, chewable tablets, and powders for oral suspension. Each dosage form has its own labeled strengths and formulation characteristics. The existence of a strength in approved labeling should not be interpreted as confirmation that a specific branded package is currently distributed or available to order.

Conventional Augmentin tablets are labeled with separate amounts of amoxicillin and clavulanic acid. The standard tablet presentations contain 250 mg/125 mg, 500 mg/125 mg, or 875 mg/125 mg. These strengths and their component ratios are examined in the dedicated Augmentin tablet products guide. Chewable tablets and oral suspensions include additional presentations with different component ratios, reflecting their distinct formulation and administration requirements.

A strength written as 875 mg/125 mg means that the product contains 875 mg of amoxicillin and 125 mg of clavulanic acid, supplied as clavulanate potassium. It does not mean that the combination contains 875 mg total active ingredients. Likewise, the concentration printed on a suspension describes the quantities of both components in a specified liquid volume, typically 5 mL after reconstitution. The separate Augmentin oral suspension guide examines labeled liquid concentrations, product identity and pharmacy packaging.

These distinctions are especially important when comparing adult tablets with pediatric or liquid presentations. The FDA permits certain formulation substitutions when the amoxicillin-to-clavulanate ratio and other labeled requirements are satisfied, but does not permit unrestricted substitution based only on the amount of amoxicillin. A pharmacist or prescriber must establish that any contemplated change is appropriate for the prescribed regimen and the particular formulation. For additional product-specific information, see the Augmentin chewable tablets guide, which addresses chewable strengths and their labeling differences.

Standard Augmentin form FDA-labeled strengths Product identification
Film-coated oral tablets 250 mg/125 mg; 500 mg/125 mg; 875 mg/125 mg Immediate-release tablets with separately specified amoxicillin and clavulanate amounts.
Chewable tablets 125 mg/31.25 mg; 200 mg/28.5 mg; 250 mg/62.5 mg; 400 mg/57 mg Chewable presentations with component ratios that must be distinguished from conventional tablets.
Powder for oral suspension 125 mg/31.25 mg; 200 mg/28.5 mg; 250 mg/62.5 mg; 400 mg/57 mg per 5 mL Liquid concentrations stated per 5 mL after preparation, with formulation-specific handling requirements.

Augmentin vs Augmentin XR vs Augmentin ES-600

The Augmentin name is associated with three recognizable product identities: standard Augmentin, Augmentin XR, and Augmentin ES-600. All contain amoxicillin and clavulanate, but the formulations are not merely alternative package names for an identical product. The FDA provides separate instructions and limitations for the extended-release and ES-600 formulations within its consolidated prescribing information.

Augmentin XR uses an extended-release tablet designed to provide a different amoxicillin exposure profile from conventional immediate-release tablets. Its labeled tablet strength is 1,000 mg/62.5 mg. The FDA explicitly states that two conventional Augmentin 500 mg tablets are not equivalent to one Augmentin XR 1,000 mg tablet. Matching an approximate amoxicillin total does not reproduce the extended-release characteristics or the clavulanate content. The separate Augmentin XR product guide explains this extended-release formulation and its distinct FDA labeling.

Augmentin ES-600 is a specifically formulated oral suspension containing 600 mg of amoxicillin and 42.9 mg of clavulanic acid per 5 mL. Its labeled uses and pediatric population differ from those of standard Augmentin products. It must not be treated as interchangeable with ordinary Augmentin suspensions or XR tablets. The clavulanate concentration and overall formulation are material differences, not insignificant labeling details. The dedicated Augmentin ES-600 guide provides a closer look at this distinct pediatric suspension and its labeled product characteristics.

For brand identification, the important conclusion is that these are related but distinct FDA-labeled formulations. A prescription or pharmacy order should preserve the specific product identity, release characteristics, and concentration. This page introduces those distinctions so readers can recognize the correct brand family; it does not provide instructions for changing prescribed formulations.

Brand identity Formulation Labeled presentation Key distinction
Augmentin Immediate-release tablets, chewables and oral suspensions Multiple strengths depending on dosage form Standard combination-antibiotic product family.
Augmentin XR Extended-release tablet 1,000 mg/62.5 mg per tablet Different amoxicillin release and exposure profile; not equivalent to conventional immediate-release tablets.
Augmentin ES-600 Powder for oral suspension 600 mg/42.9 mg per 5 mL Distinct pediatric suspension with formulation-specific labeled indications and substitution restrictions.

Brand Augmentin and Generic Amoxicillin/Clavulanate

Augmentin is a brand name, while amoxicillin and clavulanate potassium describe the active pharmaceutical ingredients. Generic products can contain the same active ingredients without carrying the Augmentin brand name. However, evaluating a generic product requires greater precision than matching the two ingredient names on a pharmacy website.

For an FDA-approved generic to be considered therapeutically equivalent to a particular reference product, the applicable regulatory requirements must be satisfied. Product-specific approval and therapeutic-equivalence information can be investigated through the FDA Orange Book. The relevant comparison includes dosage form, strength, route of administration, and the specific approved product rather than brand recognition alone. The dedicated FDA-approved Augmentin products guide explains how official approval records and product labeling can be used to distinguish branded and generic combination-drug products.

The FDA also maintains information about authorized generics, which are approved brand-name drugs marketed without the brand name on their labels. This is a different regulatory concept from an independently approved generic application. An authorized-generic listing should not be interpreted as evidence that a branded package is available at a local pharmacy or that every listed product has identical current distribution.

When a prescription is written using the brand name, state substitution rules, prescription instructions, and professional dispensing requirements determine whether a generic product may be supplied. Patients who receive a product labeled amoxicillin and clavulanate potassium rather than Augmentin should verify the dispensed strength, formulation, manufacturer, and directions with their pharmacist if anything is unclear.

For a broader explanation of generic amoxicillin/clavulanate products and their identifying characteristics, see amoxicillin/clavulanate product information. This brand page focuses on Augmentin itself and the regulatory distinctions needed to recognize its formulations.

What Infections Is Augmentin FDA-Labeled to Treat?

The FDA prescribing information describes Augmentin as a combination antibacterial indicated for specified infections caused by susceptible organisms, including designated beta-lactamase-producing microorganisms. The standard tablet, chewable, and oral-suspension formulations have labeled contexts that include certain lower respiratory tract infections, acute bacterial sinusitis, acute bacterial otitis media, skin and skin structure infections, and urinary tract infections.

These indications should not be interpreted as proof that Augmentin is the preferred treatment for every infection within a named category. For example, many respiratory symptoms are viral, and some bacterial infections can be treated using a narrower-spectrum antibiotic. Susceptibility findings, local treatment recommendations, allergy history, previous antibiotic exposure, and patient-specific risk factors can change the appropriate clinical decision.

The FDA identifies additional, formulation-specific indications for Augmentin XR and Augmentin ES-600. XR has labeled applications in community-acquired pneumonia and acute bacterial sinusitis under its specified conditions. ES-600 has labeled applications in acute bacterial sinusitis and recurrent or persistent acute otitis media within its defined pediatric population. These indication differences reinforce why the three brand identities must not be collapsed into one interchangeable product.

A valid prescription follows a clinician's assessment of whether antibacterial treatment is warranted and which product is appropriate. Augmentin is not indicated for treating the common cold, influenza, or other viral infections. The presence of an FDA-approved indication does not mean that every patient with that diagnosis should receive Augmentin.

How to Confirm a Brand Augmentin Prescription at a U.S. Pharmacy

A search result displaying Augmentin does not establish that a pharmacy has original branded Augmentin in stock. Online catalogs may display reference brand names alongside generic products, maintain historical product pages, or show strengths that are not currently available at a particular location. Patients seeking a specific branded formulation need confirmation from the dispensing pharmacy rather than relying on the existence of a product listing.

The verification process begins with a valid prescription and a clearly identified product. The pharmacy should be able to confirm whether the prescription calls for conventional Augmentin, Augmentin XR, or Augmentin ES-600 and whether the requested dosage form and strength can be dispensed. Questions about a brand requirement or permitted generic substitution should be addressed before dispensing rather than after an assumed exchange.

Pharmacy confirmation can include the dispensed product's proprietary or established name, manufacturer or labeler, National Drug Code where applicable, dosage form, strength, and package characteristics. FDA approval establishes a product's regulatory status, while the brand name identifies a proprietary product family and the manufacturer or labeler information helps identify a specific marketed presentation. These facts should be distinguished from current distribution and pharmacy stock. An NDC is a product-identification tool, not independent proof of present availability or clinical appropriateness.

If the requested branded package is unavailable, the pharmacist can explain what legally and clinically appropriate options may exist and whether the prescribing professional must authorize a change. Patients should not independently combine tablets, switch between oral suspension concentrations, or substitute XR and immediate-release products to reproduce a prescribed dose.

An online pharmacy should also be evaluated as a dispensing healthcare service, not simply as an e-commerce checkout. A legitimate U.S. prescription-pharmacy transaction requires appropriate prescription handling and compliance with applicable state and federal requirements. Claims such as guaranteed approval, prescription-free access, or automatic replacement of a prescribed product deserve particular scrutiny.

Verification point What to confirm Why it matters
Prescription status A valid prescription and applicable dispensing requirements Augmentin is a prescription-only antibacterial drug.
Product name Augmentin, Augmentin XR, Augmentin ES-600, or a named generic Related names do not always identify interchangeable formulations.
Dosage form Conventional tablet, extended-release tablet, chewable tablet, or oral suspension Release characteristics and formulation affect product identity.
Strength Both amoxicillin and clavulanate quantities Amoxicillin content alone is insufficient to identify equivalence.
Manufacturer and NDC Actual product identifiers supplied by the pharmacy Helps distinguish the dispensed product from a generic catalog entry.
Brand inventory Whether the specified branded product can actually be dispensed FDA listing does not guarantee current pharmacy stock.

Why Augmentin Formulations Cannot Always Be Substituted

The FDA labeling contains explicit rules for switching between Augmentin strengths and dosage forms. Different products can have different amoxicillin-to-clavulanate ratios, dosage forms, and release characteristics. Certain immediate-release tablets, chewable tablets, and oral suspensions may be substituted under the specific conditions in the FDA label, including matching the component ratio. Other combinations are not equivalent, even when their amoxicillin amounts appear similar.

For example, the conventional Augmentin 250 mg/125 mg tablet contains substantially more clavulanate than the 250 mg/62.5 mg chewable tablet. The FDA specifically identifies these presentations as not substitutable. Similarly, two conventional 250 mg/125 mg tablets are not an acceptable direct substitution for one 500 mg/125 mg tablet because the total clavulanate exposure differs.

The FDA identifies specific substitution options among standard immediate-release formulations. Corresponding strengths of Augmentin chewable tablets and oral suspensions may be substituted on a milligram-for-milligram basis where appropriate. Certain conventional tablet strengths also have matching suspension or chewable presentations identified in the label. These permissions are subject to the product-specific instructions and patient-population restrictions; they are not authorization for patients to change formulations independently.

The distinction extends to XR and ES-600. Augmentin XR has extended-release characteristics that conventional tablets do not reproduce. Augmentin ES-600 has a different component concentration from other Augmentin suspensions and is subject to separate labeled limitations. The FDA provides specific formulation-switching instructions, but those instructions are intended for professional medication management rather than self-directed changes.

Patients may encounter substitution questions when a branded item is unavailable, a child cannot swallow a tablet, or a pharmacy carries a different concentration of suspension. Such circumstances require pharmacist or prescriber review. Crushing or changing an extended-release formulation, estimating a liquid volume from another concentration, or replacing a prescribed medicine with leftover tablets creates avoidable medication-error risks.

The FDA label also addresses administration, preparation, and storage requirements. Reconstituted Augmentin suspensions require refrigeration and have a limited storage period specified in the labeling. Patients should follow the actual dispensed product's instructions and confirm any storage or preparation uncertainty with the pharmacy rather than assuming that all formulations are handled identically.

Important Safety and Responsible-Use Considerations

Augmentin shares important safety considerations with other penicillin-class antibiotics while also having risks associated with the amoxicillin/clavulanate combination. The FDA labeling includes contraindications for a history of serious hypersensitivity reactions to Augmentin or other beta-lactam antibacterial drugs and for previous Augmentin-associated cholestatic jaundice or hepatic dysfunction.

Potential adverse effects include diarrhea, nausea, vomiting, and skin reactions. More serious events described in the labeling include severe allergic reactions, severe cutaneous adverse reactions, liver injury, and Clostridioides difficile-associated diarrhea. Severe breathing difficulty, facial or throat swelling, or other signs of anaphylaxis require emergency medical attention. Serious or persistent adverse symptoms warrant prompt clinical assessment.

The complete medication review can also matter. The FDA prescribing information discusses interactions or precautions involving medications such as probenecid, oral anticoagulants, and allopurinol. Kidney function and other clinical characteristics may affect prescribing decisions. Patients should provide their prescriber and pharmacist with an accurate medication and allergy history rather than relying on the brand name as a safety guarantee.

Responsible antibiotic use means taking a prescribed medicine according to the clinician's instructions, not sharing it, and not saving unused doses for a future illness. A new infection needs a new assessment because the causative organism, susceptibility, and appropriate treatment can differ. Unnecessary antibiotic use can cause adverse effects and contribute to antimicrobial resistance.

For additional context about beta-lactam hypersensitivity, see penicillin allergy information. Questions about whether a patient should receive Augmentin instead of another antibiotic require individualized professional judgment and are not resolved by this product-identification guide.

Brand Availability, Generic Dispensing and Cost Questions

Brand recognition and purchasing availability are separate issues. A product can remain identifiable through FDA labeling, approval records, or historic marketing information even when a particular branded package is difficult to obtain from a specific pharmacy. Similarly, an authorized-generic or independently approved generic listing does not guarantee that the corresponding product is stocked by every retailer.

Out-of-pocket expenses can vary with the actual dispensed formulation, package, pharmacy, insurance arrangement, and applicable discounts. A general claim that brand Augmentin is always available at a fixed price would not be reliable. Pharmacy quotations and benefit information are time-sensitive and must be checked for the specific prescription.

Patients who require a branded product should ask the dispensing pharmacy what can be supplied and whether an alternative would require prescriber involvement. Product verification should precede cost comparison: a price quote for generic immediate-release tablets does not necessarily describe brand Augmentin, Augmentin XR, or Augmentin ES-600.

For the dedicated pricing and affordability discussion, see Augmentin price and cost information. This brand hub deliberately avoids presenting unverified retail offers or treating price as evidence that a product is suitable, available, or approved for an individual patient.

Frequently Asked Questions

Augmentin is a U.S. prescription antibiotic brand containing amoxicillin and clavulanate potassium. Amoxicillin is a penicillin-class antibacterial, while clavulanate inhibits certain bacterial beta-lactamase enzymes. The combination is used for specified susceptible bacterial infections when prescribed by a healthcare professional.

No. Plain amoxicillin contains one antibacterial active ingredient, while Augmentin contains amoxicillin plus clavulanate. The additional component changes the drug's activity against certain beta-lactamase-producing bacteria and introduces formulation-specific considerations. The medicines should not be exchanged without professional assessment.

Augmentin is an FDA-approved brand identity represented in U.S. prescribing and regulatory records. However, an approved brand listing does not establish that a particular branded strength or package is currently stocked by a pharmacy. A dispensing pharmacy must confirm actual supply.

The July 2026 FDA labeling identifies standard immediate-release tablets containing 250 mg/125 mg, 500 mg/125 mg, and 875 mg/125 mg of amoxicillin and clavulanic acid. Chewable tablets and oral suspensions have additional labeled strengths and different component ratios. These presentations are not freely interchangeable.

Standard Augmentin tablets are immediate-release products, while Augmentin XR uses an extended-release formulation containing 1,000 mg of amoxicillin and 62.5 mg of clavulanic acid per tablet. The FDA warns that conventional immediate-release tablets are not equivalent to Augmentin XR simply because the amoxicillin quantities appear similar.

No. Augmentin ES-600 contains 600 mg of amoxicillin and 42.9 mg of clavulanic acid per 5 mL and has distinct pediatric labeling. Its amoxicillin-to-clavulanate proportion differs from standard Augmentin suspensions. The FDA specifically restricts substitution between ES-600 and other Augmentin formulations.

An appropriate FDA-approved generic may be dispensed when permitted by the prescription and applicable substitution rules. The pharmacy must consider the specific dosage form, strength, approved product, and relevant restrictions. Not every product containing amoxicillin and clavulanate is interchangeable with every branded formulation.

No. FDA approval and published labeling establish regulatory product information, not real-time retail inventory. A pharmacy must confirm whether the exact brand, dosage form, strength, and package can be supplied for a valid prescription.

No. Augmentin is a prescription-only antibiotic in the United States. A legitimate dispensing process requires a valid prescription and compliance with applicable pharmacy regulations. Websites promising prescription-free Augmentin should not be treated as evidence of lawful or safe access.

Do not change formulations independently. The FDA permits certain substitutions between matching immediate-release formulations under specified conditions, but other strengths and formulations are not equivalent. The amounts and proportions of amoxicillin and clavulanate can differ, and XR products have distinct release characteristics. A pharmacist or prescriber must determine whether any proposed substitution is appropriate.

Augmentin has activity against some beta-lactamase-producing bacteria that may be resistant to amoxicillin alone. That does not make it universally stronger or clinically preferable. The appropriate antibiotic depends on the suspected or confirmed organism, infection, susceptibility, patient factors, and treatment guidance.

No. Augmentin is an antibacterial drug and does not treat viruses responsible for conditions such as influenza or the common cold. Unnecessary use can cause adverse effects and contribute to antibiotic resistance. Treatment decisions should follow an appropriate clinical evaluation.

Check the dispensed container label and ask the pharmacist to confirm the actual product name, manufacturer, dosage form, strength, and National Drug Code when applicable. A pharmacy website or prescription search result may use the Augmentin name even when the dispensed product is a generic.

Augmentin contains amoxicillin, a penicillin-class antibacterial. Its FDA labeling contraindicates use in patients with a history of serious hypersensitivity reactions to Augmentin or other beta-lactam antibacterial drugs. Anyone reporting a penicillin allergy should have the history evaluated by a healthcare professional before treatment.